Gene Test Identifies Breast Cancer Patients Who Can Safely Skip Chemotherapy
Findings from the OPTIMA trial show that the Prosigna test identifies patients who can safely skip chemotherapy and use hormone therapy alone.
Read MorePosted by CLP Edit Staff | Jun 9, 2026 | Breast |
Findings from the OPTIMA trial show that the Prosigna test identifies patients who can safely skip chemotherapy and use hormone therapy alone.
Read MorePosted by CLP Edit Staff | Jun 8, 2026 | Prostate |
Researchers reported that the test reduced unnecessary biopsies by up to 64% without compromising detection of aggressive prostate cancers.
Read MorePosted by CLP Edit Staff | Jun 8, 2026 | Cancer, Company News, Molecular Diagnostics |
The updated test includes additional DPYD variants recommended by the Association for Molecular Pathology to help identify patients who may be at risk for severe chemotherapy side effects.
Read MorePosted by CLP Edit Staff | Jun 8, 2026 | Dementias & Alzheimer’s, Immunoassay |
Biomarkers in midlife adults without dementia may be linked to the earliest signs of waning cognition, researchers found.
Read MorePosted by CLP Edit Staff | Jun 5, 2026 | Colorectal, Molecular Diagnostics |
The study demonstrated that patients who test positive for ctDNA “actually benefit from chemotherapy.”
Read More